6.47 0.00 (0.00%)
After hours: 4:36PM EDT
|Bid||6.44 x 1000|
|Ask||6.48 x 3000|
|Day's Range||6.44 - 6.66|
|52 Week Range||3.32 - 9.49|
|Beta (3Y Monthly)||2.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.00|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
TG Therapeutics, Inc. (TGTX), today presented the first look at the ULTIMATE I & II Phase 3 trial design and demographic data and updated Phase 2 extension trial data for ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held in Stockholm, Sweden. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer stated, “We are pleased to present the first look at the study design and patient demographics data from our Phase 3 ULTIMATE program.
TG Therapeutics, Inc. (TGTX), today announced that abstracts featuring ublituximab, the Company’s novel, glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of multiple sclerosis (RMS) have been accepted for presentation at the upcoming 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be held September 11 – 13, 2019 in Stockholm, Sweden. Abstracts are now available online and can be accessed on the ECTRIMS meeting website at www.ectrims-congress.eu.
NEW YORK, Aug. 26, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) announced with great sadness the passing of longtime Board Member, Mark Schoenebaum, MD. "Everyone at TG is.
On Monday morning, Benzinga Pro subscribers received an option alert due to an unusually large TG Therapeutics trade. Due to the relatively complex nature of the options market, options traders are generally considered to be more sophisticated than the average stock trader. In addition, large options traders are often professional, wealthy individuals or institutions, either of which could have unique insight or information about a company.
A look at the shareholders of TG Therapeutics, Inc. (NASDAQ:TGTX) can tell us which group is most powerful. Generally...
NEW YORK, Aug. 09, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the second quarter ended June 30, 2019 and recent company.
NEW YORK, Aug. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Friday, August 9, 2019 at 8:30 AM ET to discuss results.
How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced the presentation of long-term follow-up data from the Phase 2 and Open Label Extension (OLE) trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS).
While small-cap stocks, such as TG Therapeutics, Inc. (NASDAQ:TGTX) with its market cap of US$595m, are popular for...
NEW YORK, June 18, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
TG Therapeutics, Inc. (TGTX) today announced the presentation of preclinical data for TG-1801, the Company’s first-in-class anti-CD47/CD19 bispecific antibody, highlighting the synergistic effect of TG-1801 in combination with ublituximab, the Company’s anti-CD20 monoclonal antibody and umbralisib, the Company’s PI3K-delta inhibitor.
TG Therapeutics, Inc. (TGTX), today announced that the Company has confirmed its path to submit umbralisib for accelerated approval based on data from the marginal zone lymphoma (MZL) cohort of the UNITY-NHL Phase 2b trial. The Company recently had a productive Breakthrough Therapy Designation (BTD) meeting with the U.S. Food and Drug Administration (FDA) to discuss the MZL submission strategy.
TG Therapeutics, Inc. (TGTX) today presented positive interim data from the ongoing single-arm marginal zone lymphoma (MZL) cohort of its Phase 2b UNITY-NHL trial currently evaluating umbralisib as a single agent in patients with relapsed/refractory MZL. Umbralisib is an investigational, oral, once-daily PI3K delta inhibitor with unique inhibition of CK1 epsilon and is currently under development for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
Presentation scheduled for tomorrow, Wednesday, June 5, 2019, at 9:00 AM ET NEW YORK, June 04, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S..
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Michael Weiss, chairman, president and CEO of TG Therapeutics Inc. Cramer noted that TGTX is a speculative company, one that still has no revenues, but their story continues to be compelling. In the daily bar chart of TGTX, below, we can see what looks like a base pattern to me when we look at volume along with the price action.